Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
Clin Microbiol Infect. 2022 Mar;28(3):440-445. doi: 10.1016/j.cmi.2021.09.033. Epub 2021 Oct 9.
Prophylaxis with trimethoprim-sulphamethoxazole (TMP-SMZ) is recommended in Toxoplasma-seropositive allogeneic haematopoietic cell transplant (HCT) recipients to prevent reactivation, but it is associated with numerous side effects. We report our experience of a pre-emptive approach guided by a polymerase chain reaction (PCR) in patients not receiving prophylaxis.
In this retrospective, single-centre experience, seropositive recipients and seronegative recipients receiving a graft from a seropositive donor were screened by PCR for the presence of Toxoplasma gondii DNA in peripheral blood until at least 6 months after transplantation. Confirmed PCR positivity triggered a pre-emptive anti-Toxoplasma therapy. Cases of Toxoplasma reactivation (using the European Society for Blood and Marrow Transplantation definitions) were compared with four controls (without reactivation), matched in time and recipient serostatus, to identify risk factors for reactivation by multivariate analysis.
From November 2001 to August 2020, 1455 consecutive adult patients (59 cases and 1396 controls) were screened. The overall 1-year cumulative incidence of toxoplasmosis was 4.1% and the 1-year cumulative incidence in the seropositive recipients was 8.8%. Reactivation was associated with second transplant (OR 2.51, 95%CI 1.28-4.94, p 0.011), myeloablative conditioning (OR 2.24, 95%CI 1.17-4.41, p 0.011), total body irradiation (OR 2.29, 95%CI 1.17-4.44, p 0.010), acute graft-versus-host disease (GvHD) (OR 2.27, 95%CI 1.26-4.08, p 0.008) and use of high-dose corticosteroids (OR 2.08, 95%CI 1.14-3.78, p 0.018). In multivariate analysis only acute GvHD remained significant (adjusted OR 2.54, 95%CI 1.16-5.71, p 0.021).
A PCR-based pre-emptive approach might serve as an acceptable alternative for patients unable to start with or to continue TMP-SMZ prophylaxis. Acute GvHD was identified as the single independent predictor for reactivation.
在弓形虫血清阳性的异基因造血细胞移植(HCT)受者中,推荐使用复方磺胺甲噁唑(TMP-SMZ)预防以预防复发,但它与许多副作用有关。我们报告了在未接受预防治疗的患者中,通过聚合酶链反应(PCR)进行前瞻性治疗的经验。
在这项回顾性单中心研究中,通过 PCR 检测血清阳性受者和接受血清阳性供体移植物的血清阴性受者外周血中的弓形虫 DNA,直至移植后至少 6 个月。PCR 阳性确诊后,立即进行预防性抗弓形虫治疗。根据欧洲血液和骨髓移植协会的定义,将弓形虫再激活病例(cases of Toxoplasma reactivation)与 4 名(无再激活)时间和受者血清状态匹配的对照进行比较,通过多变量分析确定再激活的危险因素。
从 2001 年 11 月至 2020 年 8 月,共筛选了 1455 例连续成年患者(59 例和 1396 例对照)。总体而言,1 年累积弓形虫病发生率为 4.1%,血清阳性受者的 1 年累积发生率为 8.8%。再激活与二次移植(OR 2.51,95%CI 1.28-4.94,p 0.011)、骨髓清除性预处理(OR 2.24,95%CI 1.17-4.41,p 0.011)、全身照射(OR 2.29,95%CI 1.17-4.44,p 0.010)、急性移植物抗宿主病(GvHD)(OR 2.27,95%CI 1.26-4.08,p 0.008)和高剂量皮质类固醇的使用(OR 2.08,95%CI 1.14-3.78,p 0.018)相关。多变量分析显示仅急性 GvHD 有统计学意义(调整后的 OR 2.54,95%CI 1.16-5.71,p 0.021)。
基于 PCR 的前瞻性方法可能是不能开始或继续 TMP-SMZ 预防的患者的一种可接受的替代方法。急性 GvHD 是唯一确定的再激活的独立预测因素。